Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2009-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00262-008-0555-9PMID 18633610PMCID PMC11030637
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth

  2007cited by this paper
• Identification of an alternative Gαq-dependent chemokine receptor signal transduction pathway in dendritic cells and granulocytes

  2007cited by this paper
• Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma.

  2006cited by this paper
• Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake.

  2006influential reference
• Systemic Administration of an Attenuated, Tumor-Targeting Salmonella typhimurium to Dogs with Spontaneous Neoplasia: Phase I Evaluation

  2005influential reference
• Effect of blocking the CXCL9/10-CXCR3 chemokine system in the outcome of endothelial-target rickettsial infections.

  2004influential reference
• Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins

  2004cited by this paper
• Intratumoral Administration of Dendritic Cells Overexpressing CCL21 Generates Systemic Antitumor Responses and Confers Tumor Immunity

  2004cited by this paper
• The Domains of Apoptosis: A Genomics Perspective

  2004cited by this paper
• The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells.

  2004cited by this paper
• Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.

  2002cited by this paper
• Antitumor Effects in Mice of the Intravenous Injection of Attenuated Salmonella Typhimurium

  2002cited by this paper
• Secondary Lymphoid Tissue Chemokine Mediates T Cell-Dependent Antitumor Responses In Vivo1

  2000influential reference
• Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.

  2000cited by this paper
• CCR7 ligands, SLC/6Ckine/Exodus2/TCA4 and CKbeta-11/MIP-3beta/ELC, are chemoattractants for CD56(+)CD16(-) NK cells and late stage lymphoid progenitors.

  1999cited by this paper
• The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 beta are potent chemoattractants for in vitro- and in vivo-derived dendritic cells.

  1999cited by this paper
• Optimization of Plasmid Maintenance in the Attenuated Live Vector Vaccine Strain Salmonella typhiCVD 908-htrA

  1999cited by this paper
• The CC Chemokine Receptor-7 Ligands 6Ckine and Macrophage Inflammatory Protein-3β Are Potent Chemoattractants for In Vitro- and In Vivo-Derived Dendritic Cells

  1999cited by this paper
• Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis.

  1998cited by this paper
• The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3.

  1998cited by this paper
• Chemokines and their role in tumor growth and metastasis.

  1998cited by this paper
• A lymphocyte‐specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells

  1998cited by this paper
• Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome.

  1997cited by this paper
• Chemokines.

  1997cited by this paper
• Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10.

  1996cited by this paper
• Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo

  1995cited by this paper
• THE ROLE OF CXC CHEMOKINES AS REGULATORS OF ANGIOGENESIS

  1995cited by this paper
• Expression of human IL-1 beta in Salmonella typhimurium. A model system for the delivery of recombinant therapeutic proteins in vivo.

  1992cited by this paper
• The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas

  1991cited by this paper
• Monoclonal antibody to murine gamma interferon inhibits lymphokine- induced antiviral and macrophage tumoricidal activities

  1984cited by this paper
• MELANOTIC CANCER WITH A REPORT OF 91 CASES

  1916cited by this paper
• I. The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas

  1893cited by this paper

• Microbiome-Modulated Immunotherapy in Oncology: Current Applications and Future Prospects.

  2026cites this paper
• Live biotherapeutics in cancer therapy.

  2026cites this paper
• Genetically Modified Salmonella typhimurium: A Trojan Horse Strategy for Targeted Cancer Therapy

  2026cites this paper
• The tumor microbiome in cancer progression: mechanisms and therapeutic potential

  2025cites this paper
• Recent Advances in Bacterium‐Based Therapeutic Modalities for Melanoma Treatment

  2024cites this paper
• Bactofection, Bacterial-Mediated Vaccination, and Cancer Therapy: Current Applications and Future Perspectives

  2024cites this paper
• Exploiting bacteria for cancer immunotherapy

  2024cites this paper
• Programmable cancer treatments: Engineering biology approaches for living cures

  2024cites this paper
• Microbiome and cancer: from mechanistic implications in disease progression and treatment to development of novel antitumoral strategies

  2024cites this paper
• A Review of the Use of Native and Engineered Probiotics for Colorectal Cancer Therapy

  2024cites this paper
• Engineered bacteria in tumor immunotherapy.

  2024cites this paper
• Tumor-targeting bacteria as immune stimulants – the future of cancer immunotherapy?

  2024cites this paper
• When synthetic biology meets medicine

  2024cites this paper
• Engineering Probiotic E. coli Nissle 1917 for Release of Therapeutic Nanobodies.

  2024cites this paper
• Engineered bacteria: Strategies and applications in cancer immunotherapy

  2024cites this paper
• Bacterial live therapeutics for human diseases

  2024cites this paper
• Mouse CCL9 Chemokine Acts as Tumor Suppressor in a Murine Model of Colon Cancer

  2023cites this paper
• Salmonella typhimurium may support cancer treatment: a review

  2023cites this paper
• Safety aspects of microorganisms deliberately released into the environment

  2023cites this paper
• Clostridium Bacteria: The Team of Microscopic Oncologists

  2023cites this paper
• Attenuated Salmonella-delivered PD-1 siRNA enhances the antitumor effects of EZH2 inhibitors in colorectal cancer.

  2023cites this paper
• The role of extratumoral and intratumoral microorganisms in cancer immunotherapy

  2023cites this paper
• Engineered E. coli Nissle 1917 for delivery of bioactive IL-2 for cancer immunotherapy

  2023cites this paper
• Bacterial‐Mediated Tumor Therapy: Old Treatment in a New Context

  2023cites this paper
• Engineered microbes for cancer immunotherapy

  2022cites this paper
• Photodynamic therapy-improved oncolytic bacterial immunotherapy with FAP-encoding S. typhimurium.

  2022cites this paper
• Recombinant Attenuated Salmonella enterica as a Delivery System of Heterologous Molecules in Cancer Therapy

  2022cites this paper
• The bacteria inside human cancer cells: Mainly as cancer promoters

  2022cites this paper
• Advances in Salmonella Typhimurium-based drug delivery system for cancer therapy.

  2022cites this paper
• Bacteria-Assisted Transport of Nanomaterials to Improve Drug Delivery in Cancer Therapy

  2022cites this paper
• Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy.

  2021cites this paper
• Bacterial-based cancer therapy: An emerging toolbox for targeted drug/gene delivery.

  2021cites this paper
• Colorectal cancer treatment using bacteria: focus on molecular mechanisms

  2021cites this paper
• Del-1 enhances therapeutic efficacy of bacterial cancer immunotherapy by blocking recruitment of tumor-infiltrating neutrophils

  2021cites this paper
• Integration of Salmonella into Combination Cancer Therapy

  2021cites this paper
• Emerging Applications of Bacteria as Antitumor Agents.

  2021cites this paper
• Use of Salmonella Bacteria in Cancer Therapy: Direct, Drug Delivery and Combination Approaches

  2021cites this paper
• Bacteria and bacterial derivatives as delivery carriers for immunotherapy.

  2021cites this paper
• Innovative Approaches of Engineering Tumor-Targeting Bacteria with Different Therapeutic Payloads to Fight Cancer: A Smart Strategy of Disease Management

  2021cites this paper
• Theranostic Approaches Using Live Bacteria

  2021cites this paper
• Highlights of Immunomodulation in Salmonella-Based Cancer Therapy

  2021cites this paper
• Bacteria-Based Immune Therapies for Cancer Treatment.

  2021cites this paper
• Salmonella Typhimurium as a potential anticancer agent: A Review

  2020cites this paper
• Chlorogenic acid suppresses neutrophil recruitment to tumors by inducing apoptosis and reverse migration

  2020cites this paper
• Oral delivery of bacteria: Basic principles and biomedical applications.

  2020cites this paper
• The potential use of theranostic bacteria in cancer

  2020cites this paper
• CCR7 as a therapeutic target in Cancer.

  2020cites this paper
• Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.

  2020cites this paper
• Engineering Living Bacteria for Cancer Therapy.

  2020cites this paper
• Bacteria in cancer therapy: Strategies to improvement and future directions

  2020cites this paper
• Salmonella Typhimurium as an Anticancer Therapy: Recent Advances and Perspectives

  2019cites this paper
• Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy

  2019cites this paper
• A Review of Novel Methods of the Treatment of Cancer by Bacteria

  2019cites this paper
• Targeting Programmed Fusobacterium nucleatum Fap2 for Colorectal Cancer Therapy

  2019cites this paper
• Bacterial Targeting of Tumors

  2019cites this paper
• Genetically engineered Salmonella Typhimurium: Recent advances in cancer therapy.

  2019cites this paper
• Use of Tumor Targeting Bacteria as Cancer Therapeutic Agents and Drug Delivery Vehicles: A Conceptual Approach

  2019cites this paper
• Bacteria-cancer interactions: bacteria-based cancer therapy

  2019cites this paper
• Live Attenuated Salmonella enterica Expressing and Releasing Cell-Permeable Bax BH3 Peptide Through the MisL Autotransporter System Elicits Antitumor Activity in a Murine Xenograft Model of Human B Non-hodgkin's Lymphoma

  2019cites this paper
• Recent progress in bacterial-mediated cancer therapy

  2018cites this paper
• Bacteria in cancer therapy: beyond immunostimulation

  2018cites this paper
• Cancer Immunotherapy: Priming the Host Immune Response with Live Attenuated Salmonella enterica

  2018influential citation
• Tumour-targeting bacteria engineered to fight cancer

  2018cites this paper
• Co-Expression of a Chimeric Protease Inhibitor Secreted by a Tumor-Targeted Salmonella Protects Therapeutic Proteins from Proteolytic Degradation.

  2018cites this paper
• Infection by Salmonella enterica Promotes or Demotes Tumor Development

  2018cites this paper
• Microbiological approaches to Treating Cancer

  2018cites this paper
• A Genetically Modified attenuated Listeria Vaccine Expressing HPV16 E7 Kill Tumor Cells in Direct and Antigen-Specific Manner

  2017cites this paper
• Local application of bacteria improves safety of Salmonella-mediated tumor therapy and retains advantages of systemic infection

  2017cites this paper
• Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin

  2017cites this paper
• Bacteria as a vehicle in cancer therapy and drug delivery

  2017cites this paper
• The microbiome in anti-cancer therapy.

  2017cites this paper
• Advances in bacterial cancer therapies using synthetic biology.

  2017cites this paper
• Bacteria and genetically modified bacteria as cancer therapeutics: Current advances and challenges

  2017cites this paper
• Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities.

  2016cites this paper
• Genetically Modified Bacteria as Targeted Agent for Cancer

  2016cites this paper
• Synchronized cycles of bacterial lysis for in vivo delivery

  2016cites this paper
• Strains, Mechanism, and Perspective: Salmonella-Based Cancer Therapy

  2016cites this paper
• Drug delivery with living cells.

  2016cites this paper
• Targeted Cancer Therapy Using Engineered Salmonella typhimurium

  2016cites this paper
• Bioengineered and biohybrid bacteria-based systems for drug delivery.

  2016cites this paper
• Tumor-targeted delivery of a C-terminally truncated FADD (N-FADD) significantly suppresses the B16F10 melanoma via enhancing apoptosis

  2016cites this paper
• [Advances in tumor-therapy using genetically modified Salmonella].

  2016cites this paper
• Live-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent Delivery

  2015cites this paper
• Attenuated Salmonella enterica Typhimurium reduces tumor burden in an autochthonous breast cancer model.

  2015cites this paper
• FACULTAD DE FARMACIA UNIVERSIDAD COMPLUTENSE

  2015cites this paper
• Salmonella enterica: un aliado en la terapia contra el cáncer

  2015cites this paper
• Bacterial Cancer Therapy: How Patients Might Benefit from Salmonella Infections

  2015cites this paper
• Impediments to Enhancement of CPT-11 Anticancer Activity by E. coli Directed Beta-Glucuronidase Therapy

  2015cites this paper
• [Salmonella enterica: an ally in the therapy of cancer].

  2015cites this paper
• Potent and tumor specific: arming bacteria with therapeutic proteins.

  2015cites this paper
• Bacteria: prospective savior in battle against cancer.

  2014cites this paper
• Genetically Engineered Salmonella typhimurium for Targeted Cancer Therapy

  2014cites this paper
• Benefits of Utilizing Bacteria in Cancer Treatment

  2014cites this paper
• Tumor-specific delivery of histidine-rich glycoprotein suppresses tumor growth and metastasis by anti-angiogenesis and vessel normalization.

  2014cites this paper
• Tumor-colonizing bacteria: A potential tumor targeting therapy

  2014cites this paper
• Tumor-targeting bacterial therapy: A potential treatment for oral cancer (Review)

  2014cites this paper
• A Salmonella Typhimurium mutant strain capable of RNAi delivery

  2014cites this paper
• [Therapeutic intervention alternatives in cancer, using attenuated live bacterial vectors: Salmonella enterica as a carrier of heterologous molecules].

  2013cites this paper
• Salmonella and cancer: from pathogens to therapeutics.

  2013cites this paper
• Tumor growth control with IDO-silencing Salmonella--reply.

  2013cites this paper